AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance

Cancer Letters

Volumn 350, Issue 1-2, 2014, Pages 61-68

  Zhang, Hui ^a,b   Wang, Yi Jun ^b   Zhang, Yun Kai ^b   Wang, De Shen ^a,b   Kathawala, Rishil J ^b   Patel, Atish ^b   Talele, Tanaji T ^b   Chen, Zhe Sheng ^b   Fu, Li Wu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

ABCG2; AST1306; ATP binding cassette transporters; Multidrug resistance

Indexed keywords

5 (4,6 DIMETHYL 1,3,2 DIOXAPHOSPHORINAN 2 YL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 3 PYRIDINECARBOXYLIC ACID 2 (4 BENZHYDRYL 1 PIPERAZINYL)ETHYL ESTER P OXIDE; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; AST 1306; BREAST CANCER RESISTANCE PROTEIN; CEPHARANTHINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIRTECAN; FUMITREMORGIN C; MITOXANTRONE; PACLITAXEL; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; CELL MEMBRANE; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; SEQUENCE HOMOLOGY;

ABCG2; AST1306; ATP-BINDING CASSETTE TRANSPORTERS; MULTIDRUG RESISTANCE;

ACRYLAMIDES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOXANTRONE; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84901487015     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.04.008     Document Type: Article

References (44)

1. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
2. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
3. Dean M., Hamon Y., Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid. Res. 2001, 42:1007-1017.
4. Tiwari A.K., Sodani K., Dai C.L., Ashby C.R., Chen Z.S. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol. 2011, 12:570-594.
5. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug. Discov. 2006, 5:219-234.
6. Chen Z.S., Tiwari A.K. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 2011, 278:3226-3245.
7. Dean M., Allikmets R. Complete characterization of the human ABC gene family. J. Bioenergy Biomembr. 2001, 33:475-479.
8. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54:5902-5910.
9. Chen Z.S., Furukawa T., Sumizawa T., Ono K., Ueda K., Seto K., Akiyama S.I. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol. Pharmacol. 1999, 55:921-928.
10. Breuninger L.M., Paul S., Gaughan K., Miki T., Chan A., Aaronson S.A., Kruh G.D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995, 55:5342-5347.
11. Kruh G.D., Guo Y., Hopper-Borge E., Belinsky M.G., Chen Z.S. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007, 453:675-684.
12. R.J. Kathawala, Y.J. Wang, C.R. Ashby Jr, Z.S. Chen, Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs, Chinese J Cancer, 2013.
13. R.J. Kathawala, K. Sodani, K. Chen, A. Patel, A.H. Abuznait, N. Anreddy, Y.L. Sun, A. Kaddoumi, C.R. Ashby, Jr., Z.S. Chen, Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study, Mol. Cancer Ther., 2014.
14. Suzuki M., Suzuki H., Sugimoto Y., Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. 2003, 278:22644-22649.
15. Sun Y.L., Kathawala R.J., Singh S., Zheng K., Talele T.T., Jiang W.Q., Chen Z.S. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Anticancer Drugs 2012, 23:865-873.
16. Shukla S., Sauna Z.E., Ambudkar S.V. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 2008, 22:445-447.
17. Goldberg H., Ling V., Wong P.Y., Skorecki K. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun. 1988, 152:552-558.
18. Sodani K., Patel A., Kathawala R.J., Chen Z.S. Multidrug resistance associated proteins in multidrug resistance. Chinese J. Cancer 2012, 31:58-72.
19. Zheng L.S., Wang F., Li Y.H., Zhang X., Chen L.M., Liang Y.J., Dai C.L., Yan Y.Y., Tao L.Y., Mi Y.J., Yang A.K., To K.K., Fu L.W. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS ONE 2009, 4:e5172.
20. Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., Ashby C.R., Huang Y., Robey R.W., Liang Y.J., Chen L.M., Shi C.J., Ambudkar S.V., Chen Z.S., Fu L.W. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008, 68:7905-7914.
21. Shi Z., Tiwari A.K., Shukla S., Robey R.W., Kim I.W., Parmar S., Bates S.E., Si Q.S., Goldblatt C.S., Abraham I., Fu L.W., Ambudkar S.V., Chen Z.S. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem. Pharmacol. 2009, 77:781-793.
22. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M., Harper M.E., Barrow D., Wakeling A.E., Nicholson R.I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044.
23. Xie H., Lin L., Tong L., Jiang Y., Zheng M., Chen Z., Jiang X., Zhang X., Ren X., Qu W., Yang Y., Wan H., Chen Y., Zuo J., Jiang H., Geng M., Ding J. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS ONE 2011, 6:e21487.
24. Henrich C.J., Bokesch H.R., Dean M., Bates S.E., Robey R.W., Goncharova E.I., Wilson J.A., McMahon J.B. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J. Biomol. Screen 2006, 11:176-183.
25. Robey R.W., Honjo Y., Morisaki K., Nadjem T.A., Runge S., Risbood M., Poruchynsky M.S., Bates S.E. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 2003, 89:1971-1978.
26. Akiyama S., Fojo A., Hanover J.A., Pastan I., Gottesman M.M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat. Cell Mol. Genet. 1985, 11:117-126.
27. Sun Y.L., Chen J.J., Kumar P., Chen K., Sodani K., Patel A., Chen Y.L., Chen S.D., Jiang W.Q., Chen Z.S. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS ONE 2013, 8:e55576.
28. Muller M., Yong M., Peng X.H., Petre B., Arora S., Ambudkar S.V. Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry 2002, 41:10123-10132.
29. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
30. Sodani K., Tiwari A.K., Singh S., Patel A., Xiao Z.J., Chen J.J., Sun Y.L., Talele T.T., Chen Z.S. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem. Pharmacol. 2012, 83:1613-1622.
31. D. Yang, R.J. Kathawala, E.E. Chufan, A. Patel, S.V. Ambudkar, Z.S. Chen, X. Chen, Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP), Future Oncology, 2013.
32. Zhao X.Q., Xie J.D., Chen X.G., Sim H.M., Zhang X., Liang Y.J., Singh S., Talele T.T., Sun Y., Ambudkar S.V., Chen Z.S., Fu L.W. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol. Pharmacol. 2012, 82:47-58.
33. Patel A., Tiwari A.K., Chufan E.E., Sodani K., Anreddy N., Singh S., Ambudkar S.V., Stephani R., Chen Z.S. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother. Pharmacol. 2013, 72:189-199.
34. Deng W., Dai C.L., Chen J.J., Kathawala R.J., Sun Y.L., Chen H.F., Fu L.W., Chen Z.S. Tandutinib. Oncol. Rep. 2013, 29:2479-2485.
35. K. Sodani, A. Patel, N. Anreddy, S. Singh, D.H. Yang, R.J. Kathawala, P. Kumar, T.T. Talele, Z.S. Chen, Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo, Biochem. Pharmacol., 2014.
36. Tiwari A.K., Sodani K., Dai C.L., Abuznait A.H., Singh S., Xiao Z.J., Patel A., Talele T.T., Fu L., Kaddoumi A., Gallo J.M., Chen Z.S. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett. 2013, 328:307-317.
37. Honjo Y., Hrycyna C.A., Yan Q.W., Medina-Perez W.Y., Robey R.W., van de Laar A., Litman T., Dean M., Bates S.E. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 2001, 61:6635-6639.
38. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
39. Cohen M.H., Johnson J.R., Chen Y.F., Sridhara R., Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005, 10:461-466.
40. Cohen M.H., Williams G.A., Sridhara R., Chen G., Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8:303-306.
41. Conte P., Guarneri V. The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer. Clin. Breast Cancer 2012, 12:157-166.
42. Geourjon C., Orelle C., Steinfels E., Blanchet C., Deleage G., Di Pietro A., Jault J.M. A common mechanism for ATP hydrolysis in ABC transporter and helicase superfamilies. Trends Biochem. Sci. 2001, 26:539-544.
43. Nicolle E., Boumendjel A., Macalou S., Genoux E., Ahmed-Belkacem A., Carrupt P.A., Di Pietro A. QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv. Drug Deliv. Rev. 2009, 61:34-46.
44. Shi Z., Peng X.X., Kim I.W., Shukla S., Si Q.S., Robey R.W., Bates S.E., Shen T., Ashby C.R., Fu L.W., Ambudkar S.V., Chen Z.S. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007, 67:11012-11020.